MA34450B1 - Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique - Google Patents
Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutiqueInfo
- Publication number
- MA34450B1 MA34450B1 MA35637A MA35637A MA34450B1 MA 34450 B1 MA34450 B1 MA 34450B1 MA 35637 A MA35637 A MA 35637A MA 35637 A MA35637 A MA 35637A MA 34450 B1 MA34450 B1 MA 34450B1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- therapeutic use
- imidazopyridine derivatives
- phenyl ring
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention porte sur des composés correspondant à la formule (I) : R4 NN R1 O R2 R3 (I) 5 6 7 8, dans laquelle R2 et R3 forment ensemble, avec les atomes de carbone du noyau phényle auquel ils sont liés, un hétérocycle azoté à 6 chaînons correspondant à l'une des formules (A) (B) ou (C) ci-après : N N O O Ra Ra' N N O Rb Rb' N O Rc Rc'' Rc' (A) (B) (C), les traits ondulés représentant le noyau phényle auquel R2 et R3 sont liés. L'invention porte aussi sur un procédé pour la préparation de ces composés et sur leur utilisation thérapeutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1055475A FR2962437B1 (fr) | 2010-07-06 | 2010-07-06 | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
PCT/IB2011/052954 WO2012004732A1 (fr) | 2010-07-06 | 2011-07-04 | Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34450B1 true MA34450B1 (fr) | 2013-08-01 |
Family
ID=43383651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35637A MA34450B1 (fr) | 2010-07-06 | 2011-07-04 | Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique |
Country Status (36)
Country | Link |
---|---|
US (2) | US8759344B2 (fr) |
EP (1) | EP2590976B1 (fr) |
JP (1) | JP5889295B2 (fr) |
KR (1) | KR101820548B1 (fr) |
CN (1) | CN103080111B (fr) |
AR (1) | AR082112A1 (fr) |
AU (1) | AU2011275427B2 (fr) |
BR (1) | BR112013000273B1 (fr) |
CA (1) | CA2804915C (fr) |
CL (1) | CL2013000016A1 (fr) |
CO (1) | CO6650360A2 (fr) |
CR (1) | CR20120643A (fr) |
CY (1) | CY1117374T1 (fr) |
DK (1) | DK2590976T3 (fr) |
EA (1) | EA022690B1 (fr) |
EC (1) | ECSP13012363A (fr) |
ES (1) | ES2556754T3 (fr) |
FR (1) | FR2962437B1 (fr) |
GT (1) | GT201200346A (fr) |
HR (1) | HRP20151309T1 (fr) |
HU (1) | HUE025639T2 (fr) |
IL (1) | IL223832A (fr) |
MA (1) | MA34450B1 (fr) |
MX (1) | MX2012015120A (fr) |
NI (1) | NI201200192A (fr) |
NZ (1) | NZ604973A (fr) |
PE (1) | PE20130651A1 (fr) |
PL (1) | PL2590976T3 (fr) |
PT (1) | PT2590976E (fr) |
SG (1) | SG186396A1 (fr) |
SI (1) | SI2590976T1 (fr) |
TN (1) | TN2012000608A1 (fr) |
TW (1) | TWI520961B (fr) |
UY (1) | UY33488A (fr) |
WO (1) | WO2012004732A1 (fr) |
ZA (1) | ZA201209632B (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2962437B1 (fr) | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
WO2012088266A2 (fr) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
FR2985185B1 (fr) * | 2012-01-04 | 2013-12-27 | Sanofi Sa | Utilisation en therapeutique de derives d'imidazopyridine |
ME02651B (fr) | 2012-06-13 | 2017-06-20 | Incyte Holdings Corp | Composés tricycliques substitués utilisés comme inhibiteurs de fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
CA2909207C (fr) | 2013-04-19 | 2021-11-02 | Incyte Corporation | Heterocycles bicycliques utilises en tant qu'inhibiteurs de fgfr |
US9550771B2 (en) * | 2013-09-11 | 2017-01-24 | Genentech, Inc. | Keto-imidazopyridine derivatives as RORc modulators |
ES2914072T3 (es) | 2014-08-18 | 2022-06-07 | Eisai R&D Man Co Ltd | Sal de derivado de piridina monocíclico y su cristal |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (fr) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
US9640143B1 (en) * | 2016-01-22 | 2017-05-02 | Sony Corporation | Active video projection screen coordinating grayscale values of screen with color pixels projected onto screen |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CN111712245A (zh) | 2018-03-28 | 2020-09-25 | 卫材R&D管理有限公司 | 用于肝细胞癌的治疗剂 |
BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
WO2019213544A2 (fr) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation |
WO2020185532A1 (fr) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
WO2021146424A1 (fr) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
CN114380752A (zh) * | 2020-10-22 | 2022-04-22 | 南开大学 | 一种制备n-取代-2,4-喹唑啉二酮类化合物的合成方法 |
TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為fgfr抑制劑之三環雜環 |
CN114016060B (zh) * | 2021-11-23 | 2023-05-02 | 南昌大学 | 一种酚类化合物的合成方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102808D0 (sv) | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | New compounds |
FR2838123B1 (fr) | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
FR2851563B1 (fr) | 2003-02-26 | 2005-04-22 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
FR2859997B1 (fr) * | 2003-09-18 | 2006-02-03 | Sanofi Synthelabo | Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant. |
AP2006003517A0 (en) | 2003-09-25 | 2006-02-28 | Janssen Pharmaceutica Nv | Hiv replication purine derivatives. |
FR2865934B1 (fr) | 2004-02-05 | 2006-05-05 | Sanofi Synthelabo | Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne |
WO2006057946A2 (fr) * | 2004-11-22 | 2006-06-01 | Threshold Pharmaceuticals, Inc. | Agents anticancereux de liaison à la tubuline et leurs prodrogues |
FR2883286B1 (fr) * | 2005-03-16 | 2008-10-03 | Sanofi Aventis Sa | NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
CN1733742A (zh) * | 2005-07-12 | 2006-02-15 | 浙江大学 | 苯并三嗪衍生物的制备及用途 |
FR2893616B1 (fr) | 2005-11-23 | 2008-01-04 | Sanofi Aventis Sa | Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant |
FR2896247B1 (fr) * | 2006-01-13 | 2008-02-29 | Sanofi Aventis Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
EP1891955A1 (fr) | 2006-07-24 | 2008-02-27 | Sanofi-Aventis | Utilisation de dérivés de indolizines, inhibiteurs de FGF, pour la préparation d'un médicament pour le traitement d'affections dégénératives des articulations |
CN1887878A (zh) * | 2006-07-26 | 2007-01-03 | 浙江大学 | 三嗪氮氧化物及合成方法和用途 |
WO2008085302A1 (fr) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Analogues de l'imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires |
CN101239978A (zh) | 2008-03-05 | 2008-08-13 | 南方医科大学 | 一种咪唑并吡啶类化合物 |
CA2779951A1 (fr) | 2009-11-06 | 2011-05-12 | Piramal Life Sciences Limited | Derives d'imidazopyridine |
FR2962437B1 (fr) | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
-
2010
- 2010-07-06 FR FR1055475A patent/FR2962437B1/fr not_active Expired - Fee Related
-
2011
- 2011-07-04 BR BR112013000273-5A patent/BR112013000273B1/pt active IP Right Grant
- 2011-07-04 PE PE2013000005A patent/PE20130651A1/es not_active Application Discontinuation
- 2011-07-04 JP JP2013517656A patent/JP5889295B2/ja active Active
- 2011-07-04 MX MX2012015120A patent/MX2012015120A/es active IP Right Grant
- 2011-07-04 NZ NZ604973A patent/NZ604973A/en not_active IP Right Cessation
- 2011-07-04 SI SI201130684T patent/SI2590976T1/sl unknown
- 2011-07-04 PL PL11743633T patent/PL2590976T3/pl unknown
- 2011-07-04 PT PT117436337T patent/PT2590976E/pt unknown
- 2011-07-04 ES ES11743633.7T patent/ES2556754T3/es active Active
- 2011-07-04 HU HUE11743633A patent/HUE025639T2/en unknown
- 2011-07-04 MA MA35637A patent/MA34450B1/fr unknown
- 2011-07-04 AU AU2011275427A patent/AU2011275427B2/en active Active
- 2011-07-04 US US13/808,503 patent/US8759344B2/en active Active
- 2011-07-04 EP EP11743633.7A patent/EP2590976B1/fr active Active
- 2011-07-04 SG SG2012093464A patent/SG186396A1/en unknown
- 2011-07-04 DK DK11743633.7T patent/DK2590976T3/en active
- 2011-07-04 CN CN201180042933.1A patent/CN103080111B/zh active Active
- 2011-07-04 KR KR1020137002987A patent/KR101820548B1/ko active IP Right Grant
- 2011-07-04 CA CA2804915A patent/CA2804915C/fr active Active
- 2011-07-04 EA EA201291414A patent/EA022690B1/ru not_active IP Right Cessation
- 2011-07-04 WO PCT/IB2011/052954 patent/WO2012004732A1/fr active Application Filing
- 2011-07-05 AR ARP110102398A patent/AR082112A1/es active IP Right Grant
- 2011-07-06 TW TW100123929A patent/TWI520961B/zh active
- 2011-07-06 UY UY0001033488A patent/UY33488A/es not_active Application Discontinuation
-
2012
- 2012-12-17 CR CR20120643A patent/CR20120643A/es unknown
- 2012-12-19 ZA ZA2012/09632A patent/ZA201209632B/en unknown
- 2012-12-19 TN TNP2012000608A patent/TN2012000608A1/en unknown
- 2012-12-20 GT GT201200346A patent/GT201200346A/es unknown
- 2012-12-20 NI NI201200192A patent/NI201200192A/es unknown
- 2012-12-24 IL IL223832A patent/IL223832A/en active IP Right Grant
-
2013
- 2013-01-03 CL CL2013000016A patent/CL2013000016A1/es unknown
- 2013-01-03 EC ECSP13012363 patent/ECSP13012363A/es unknown
- 2013-01-04 CO CO13001348A patent/CO6650360A2/es not_active Application Discontinuation
-
2014
- 2014-05-01 US US14/267,272 patent/US9452164B2/en active Active
-
2015
- 2015-12-01 HR HRP20151309TT patent/HRP20151309T1/hr unknown
- 2015-12-15 CY CY20151101146T patent/CY1117374T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34450B1 (fr) | Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique | |
MA34451B1 (fr) | Dérivés de l'indolizine, procédé pour leur préparation, et leur utilisation thérapeutique | |
MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
MA35826B1 (fr) | Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk | |
MA35128B1 (fr) | Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite | |
MA34147B1 (fr) | Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales | |
MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
MA31865B1 (fr) | Dérivés isoxazolo-pyridine | |
MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
MA30932B1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase | |
MA35422B1 (fr) | Imidazopyridazines amino-substituees | |
MA33636B1 (fr) | Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
MA38935B1 (fr) | Dérivés de diazacarbazole à titre de ligands tau-pet | |
TN2016000014A1 (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
TN2010000025A1 (fr) | Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
MA38260A1 (fr) | Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3 | |
MA34094B1 (fr) | Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 | |
MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
MA33320B1 (fr) | Derives de rifamycine | |
TN2011000550A1 (fr) | Derives de cyclopenta[c] pyrrolyla lkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique | |
MA30540B1 (fr) | Derives de quinolines et compositions pharmaceutiques de ces derives. | |
MA33222B1 (fr) | 5-alcynylpyridines |